- Investing.com
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Metrics to compare | GRAL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGRALPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.5x | −3.2x | −0.6x | |
PEG Ratio | −0.12 | −0.03 | 0.00 | |
Price/Book | 1.7x | 3.2x | 2.6x | |
Price / LTM Sales | 27.3x | 14.5x | 3.3x | |
Upside (Analyst Target) | 4.1% | 28.5% | 42.7% | |
Fair Value Upside | Unlock | −28.5% | 4.7% | Unlock |